Skip to main content
Publications
Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Bogler O, Raissi A, Colacci M, Beaman A, Biering-Sorensen T, Cressman A, Detsky A, Gosset A, Lassen MH, Kandel C, Khaykin Y, Barbosa D, Lapointe-Shaw L, MacFadden DR, Pearson A, Perkins BA, Rothman KJ, Skaarup KG, Weagle R, Yarnell C, Sholzberg M, Hodzic-Santor B, Lovblom E, Zipursky J, Quinn KL, Fralick M. Association between diabetes and mortality among adult patients hospitalized with COVID-19: a cohort study of hospitalized adults in Ontario, Canada, and Copenhagen, Denmark. Can J Diabetes. 2023 Jun;47(4):352-8. doi: 10.1016/j.jcjd.2023.02.005
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.